Investors sold shares of Gilead Sciences, Inc. (NASDAQ:GILD) on strength during trading on Thursday. $61.85 million flowed into the stock on the tick-up and $110.89 million flowed out of the stock on the tick-down, for a money net flow of $49.04 million out of the stock. Of all stocks tracked, Gilead Sciences had the 26th highest net out-flow for the day. Gilead Sciences traded up $0.93 for the day and closed at $76.58

A number of equities analysts recently weighed in on GILD shares. Zacks Investment Research downgraded shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Piper Jaffray Companies set a $85.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, September 12th. ValuEngine downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Monday, August 20th. BidaskClub downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Saturday, August 18th. Finally, Mizuho restated a “buy” rating and set a $94.00 target price on shares of Gilead Sciences in a report on Friday, August 10th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and a consensus target price of $88.30.

The company has a current ratio of 3.00, a quick ratio of 2.92 and a debt-to-equity ratio of 1.23. The stock has a market capitalization of $97.21 billion, a P/E ratio of 8.95, a price-to-earnings-growth ratio of -3.81 and a beta of 1.02.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, July 25th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Zacks’ consensus estimate of $1.56 by $0.35. Gilead Sciences had a net margin of 9.52% and a return on equity of 41.57%. The firm had revenue of $5.65 billion during the quarter, compared to analysts’ expectations of $5.20 billion. During the same period in the previous year, the business posted $2.56 earnings per share. The company’s revenue for the quarter was down 20.9% compared to the same quarter last year. equities analysts predict that Gilead Sciences, Inc. will post 6.56 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 27th. Shareholders of record on Friday, September 14th will be given a dividend of $0.57 per share. The ex-dividend date is Thursday, September 13th. This represents a $2.28 dividend on an annualized basis and a yield of 2.98%. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction on Wednesday, August 1st. The shares were sold at an average price of $77.85, for a total transaction of $3,892,500.00. Following the completion of the transaction, the director now directly owns 3,067,762 shares of the company’s stock, valued at $238,825,271.70. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last ninety days, insiders have sold 150,000 shares of company stock valued at $11,141,000. Company insiders own 1.30% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its position in shares of Gilead Sciences by 11.6% in the second quarter. Bank of New York Mellon Corp now owns 30,936,970 shares of the biopharmaceutical company’s stock valued at $2,191,575,000 after acquiring an additional 3,221,439 shares during the period. Northern Trust Corp boosted its position in shares of Gilead Sciences by 2.0% in the second quarter. Northern Trust Corp now owns 16,823,192 shares of the biopharmaceutical company’s stock valued at $1,191,754,000 after acquiring an additional 325,246 shares during the period. Sanders Capital LLC boosted its position in shares of Gilead Sciences by 7.0% in the second quarter. Sanders Capital LLC now owns 10,579,575 shares of the biopharmaceutical company’s stock valued at $804,126,000 after acquiring an additional 696,200 shares during the period. Boston Partners boosted its position in shares of Gilead Sciences by 3.1% in the second quarter. Boston Partners now owns 8,290,507 shares of the biopharmaceutical company’s stock valued at $587,300,000 after acquiring an additional 245,805 shares during the period. Finally, OppenheimerFunds Inc. boosted its position in shares of Gilead Sciences by 0.3% in the second quarter. OppenheimerFunds Inc. now owns 7,038,387 shares of the biopharmaceutical company’s stock valued at $498,599,000 after acquiring an additional 22,916 shares during the period. 77.95% of the stock is owned by institutional investors.

Gilead Sciences Company Profile (NASDAQ:GILD)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Further Reading: How to Use the New Google Finance Tool

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.